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leus occurs in 10% to 20% of patients undergoing colorectal surgery. 1 It is characterized by a delayed return of normal bowel function, leading to abdominal distension, nausea, and delayed fecal evacuation, which may last up to 10 days. 2 Once regarded as an inevitable consequence of surgery, it is now recognized as a research priority by national organizations, such as the Association of Coloproctology of Great Britain and Ireland. 3 Many interventions to reduce or prevent ileus have been tested, but its management remains an unmet clinical need. 4 Uncertainty over the pathophysiology of ileus has limited previous research, and this has restricted the integration of new interventions into clinical practice. 4 Recent evidence has identified intestinal inflammation and neurogenic dysfunction as key mechanisms in its development. 5 Other mechanisms, such as the effects of opioid analgesia on µ-opioid receptors and the effect of volatile anesthetic gases, are also implicated. Enhanced recovery protocols may improve ileus through fast-track care pathways, which aim to maintain normal organ function and reduce the postoperative stress response. 6 Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended by enhanced recovery protocols after elective colorectal surgery. 7 They are necessary for avoiding undesirable effects of opioid analgesia, such as constipation, sedation, and respiratory depression. Their anti-inflammatory properties may also be valuable for accelerating the recovery of bowel function by inhibiting the synthesis of prostaglandins and reducing neuromuscular dysfunction. 5 On the other hand, the use of NSAIDs after colorectal surgery is controversial. Their nephrotoxic properties increase the risk of acute kidney injury, which is associated with increased 1-year mortality after noncardiac surgery. 8 They may also be associated with an increased risk of anastomotic leak according to some observational studies. 9, 10 The opioid-sparing and anti-inflammatory properties of NSAIDs are attractive in the postoperative setting. The aim of this review was to explore the safety and efficacy of NSAIDs to improve GI recovery after colorectal surgery from previous literature. This did not seek to determine a definitive answer but aimed to collate the highest-quality available evidence and consider opportunities for future research in an area of considerable uncertainty.
PATIENTS AND METHODS

Study Design
This study was registered prospectively on the PROSPERO database of systematic reviews (CRD42018087461). The results are reported according to the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines.
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Searches
A search strategy was devised to identify randomized controlled trials (RCTs) assessing the effect of NSAIDs on GI recovery after colorectal surgery (Supplemental Digital Content 1, http://links.lww.com/DCR/A808). The final searches were performed by 2 independent investigators on January 3, 2018, using MEDLINE (via OvidSP), EM-BASE (via OvidSP), and the Cochrane Database of Systematic Reviews (S.J.C. and J.G.). Both investigators screened study titles for relevance before inspection of abstracts and full-text articles, and discrepancies were resolved through discussion and involvement of a third investigator (M.A.). Reference lists were inspected for additional eligible studies. The ClinicalTrials.gov register was queried across the same time period for ongoing or completed (but unpublished) RCTs using the search terms ileus AND NSAID OR nonsteroidal anti-inflammatory drug OR cyclooxygenase OR COX.
Eligibility Criteria
All of the RCTs including adult patients (age ≥18 y) undergoing elective colorectal surgery were eligible for inclusion. Eligible studies had to assess the effect of NSAIDs (irrespective of cyclooxygenase (COX)-1 or COX-2 selectivity) on GI recovery or length of hospital stay as a primary outcome. If the primary outcome was unclear, the effect of NSAIDs on GI recovery had to be a major focus of the study, informed through inspection of clinical trial registries and correspondence with the authors, if necessary. RCTs published online or in print up to January 3, 2018, were included. All of the other nonrandomized study designs, grey literature, and articles published in non-English languages were excluded.
Outcomes
The main outcome of interest was GI recovery. Wide variation in the choice of outcome measures between studies was anticipated, so these were not prespecified. 12 Relevant outcomes included (but were not limited to) time until first flatus, stool, and tolerance to oral intake. Secondary outcomes included morphine consumption and the incidence of postoperative complications.
Definitions
NSAIDs were defined as inhibitors of COX-1 and/or COX-2 enzymes. Colorectal surgery was defined as any surgery involving the lower GI tract (cecum to anus) with access obtained through the peritoneum. RCTs were defined as interventional studies involving random allocation of participants to ≥2 study arms, irrespective of phase or randomized design.
Data Extraction
Extraction of data was performed by a single investigator and checked by a second (S.J.C. and M.A.). Clinical data fields included site of surgery (colon versus rectum versus both), operative approach (open versus laparoscopic versus robotic), NSAID type/regimen, and control drug type/regimen. Other descriptive data fields included study sample size, study setting (single or multicenter), blinding status, country of origin, and year of publication. Clarification of missing or other desirable data was sought from study authors by e-mail.
Assessment of Bias
The Cochrane Tool for Assessing Risk of Bias was used to assess eligible RCTs according to domains of selection, performance, detection, attrition, and reporting bias. 13 Assessments of all domains were performed by 2 independent investigators (S.J.C. and J.G.). An overall status of high or low risk of bias was assigned to each RCT, with unclear risk determined to be an indicator of bias because of inadequate reporting.
Statistical Analysis
Descriptive statistics were used to present summary data. Quantitative meta-analysis was not initially planned because of anticipated variation in outcome reporting. 12, 14 When inspected, the data were determined to be of sufficient homogeneity to consider a quantitative synthesis of key outcomes. Studies were pooled together using metaanalysis models where appropriate to estimate the effects of NSAIDs on GI recovery time. In the case of multiarm trials, the arms receiving NSAIDs were grouped together to avoid comparisons of the same groups within the same meta-analysis. Measures of central tendency, when different from the mean, were estimated by using the median value. SDs were used as a measure of central tendency. Where studies did not report SD as a measure of central tendency, the SD was calculated. We used previously studied methods to estimate spread of data, should the SD be unavailable. 15 In the case where no estimates of central tendency were reported in the main study, we imputed the average central tendency value for all of the studies included. In the case where sample size was <15 patients, the SDs were derived from simulated distributions based on the appropriate time it would take for bowel function to be regained following a similar operation. Where time data were expressed in days, we converted to hours by multiplying by a factor of 24. Data were pooled using generalized-inverse variance models. Fixed-effects models were used if there were <25 patients per arm of the trial, and random-effects models were used where there were ≥4 trials and the presence of either statistical or clinical heterogeneity. Statistical heterogeneity was measured using the I2 statistic and interpreted as follows: ≤25%, low heterogeneity; 25% to 50%, moderate heterogeneity; and >50%, high heterogeneity. When statistical heterogeneity was identified, studies were examined for possible sources of this. Estimates of effect size are represented as weighted mean difference per hour after operation, alongside the corresponding 95% CI. Funnel plots were visually inspected to identify publication bias. Statistical significance was taken at the level of p < 0.05. Analyses were performed in R version 3.3.2 (https://www.r-project.org/) and RevMan version 5.3 (https://community.cochrane.org/help/ tools-and-software/revman-5).
RESULTS
Study Characteristics
Of 179 studies initially identified, 6 RCTs involving 563 randomly assigned participants met the criteria for inclusion ( Fig. 1) . [16] [17] [18] [19] [20] [21] Most RCTs were single center (n = 5/6 (83.3%)), involving surgery of both the colon and rectum (n = 5/6 (83.3%)), using an open approach (n = 5/6 (83.3%); Table 1 ). All of the studies were double blinded, and 5 of 6 were low risk of bias. The single study with high risk of bias did not meet its recruitment target because of temporary suspension over higher-than-expected rates of anastomotic leak. After an interim safety analysis, the study continued but did not accrue sufficient participants.
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Study Interventions
Four RCTs tested nonselective NSAIDs, 1 tested a COX-2 selective NSAID (valdecoxib), and 1 tested both ( Table 2 ). The most commonly tested NSAID was ketorolac in 3 RCTs. 17, 20, 21 NSAID regimens differed in their duration, with 4 studies administering the drug postoperatively for a prespecified duration of time (6 h to 5 d), and 2 discontinuing the drug according to individual analgesia requirements. In most studies (n = 5/6 (83.3%)), both NSAID and control drugs were administered in combination with/alongside intravenous patient-controlled morphine.
GI Recovery
The time to first passage of flatus was reported in 5 of 6 included RCTs. The passage of flatus was significantly faster in patients receiving an NSAID (pooled n = 277) compared with controls (pooled n = 198) by a mean difference of -17.73 hours (95% CI, -21.26 to -14.19 h; p < 0.001; Fig. 2A ). The statistical heterogeneity was low (I2 = 12%). The time to first passage of stool was also reported in 5 of 6 included RCTs. The passage of stool was significantly faster in patients receiving an NSAID (pooled n = 294) compared with control subjects (pooled n = 211) by a mean difference of -9.52 hours (95% CI, -14.74 to -4.79 h; p < 0.001; Fig. 2B ). The statistical heterogeneity was low (I2 = 17%). Time to first oral tolerance was reported in 3 of 6 included RCTs. Oral intake was tolerated faster in patients receiving an NSAID (pooled n = 205) compared with control subjects (pooled n = 128) by a mean difference of -12.00 hours (95% CI, -18.01 to -5.99; p < 0.001; Fig. 2C ). There was no statistical heterogeneity (I2 = 0%). Examination of funnel plots identified no publication bias (Supplemental Digital Content 2, http://links.lww.com/ DCR/A809).
Morphine Consumption
Comparisons of morphine consumption were reported in 5 of 6 RCTs (Table 3 ). In 4 of these, morphine consumption was significantly lower in the NSAID group (reduction in total consumption, 12.9-30.0 mg) and in 1 study, the duration of patient-controlled morphine was significantly reduced (60 vs 72 h; p < 0.001). This finding was accompanied by improved GI recovery (eg, time to first flatus, stool, and oral tolerance) in all 4 RCTs. Conversely, 1 study showed no difference in morphine consumption between NSAID groups and placebo (73 and 60 vs 80 mg; p = 0.704), despite a quicker return of flatus and stool in patients receiving NSAIDs. 16 Another study demonstrated no significant correlation between findings of improved GI recovery and reduced morphine consumption when modeled using simple logistical regression. 17 A single study reported significantly reduced expression of proinflammatory cytokines (interleukin 6 and interleukin 8) at multiple postoperative time points in the NSAID group (end of surgery, 6 h, and 24 h) but did not report morphine consumption.
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Postoperative Complications
There were no significant differences in the incidence of postoperative complications between NSAID and control groups in any of the studies (Table 4 ). The impact of NSAIDs on renal function was reported in only 1 RCT. 16 No differences in creatinine clearance were noted between NSAID and control groups on days 1, 3, and 5 after surgery. The incidence of anastomotic leak was similar between groups in most studies, however 1 RCT was temporarily suspended because of concerns over a disproportionate number of anastomotic leaks in the NSAID (ketorolac) group (final incidence: n = 4/22 (18.0%) vs n = 1/22 (4.5%)). 20 With no previous precedent for this, it was determined to represent an anomalous observation.
Search using pre-defined search terms (supplementary table) Total search: n = 179
Titles and abstracts reviewed: n = 146
Full-text articles reviewed: n = 128
Provisional eligibility: n = 6
Final eligibility: 6 articles
Exclude duplicates (n = 33)
Exclude studies (n = 18) (Nonrandomized/not colorectal surgery)
Exclude studies (n = 122) (Nonrandomized/not colorectal surgery)
Studies added from reference lists (n = 0) The study was terminated early and was underpowered according to a prospective power calculation. 
Registered Studies
Of 19 study records identified on the ClinicalTrials.gov register, 2 eligible RCTs composing a total planned recruitment of 180 participants were identified ( Table 5) . One of these (NCT02790203) will test the COX-2 inhibitor celecoxib using simple measures of GI recovery (return of flatus and stool). The other (NCT02958566) will test ketorolac (nonspecific COX inhibitor) within a multimodal, opioid-sparing strategy using measures of bowel function and economic costs.
DISCUSSION
This review demonstrated an improvement in GI recovery in patients receiving NSAIDs after colorectal surgery. This was in the absence of increased complications, but low event rates in each of the included studies limited this interpretation. Although an opioid-sparing effect of NSAIDs was clearly apparent, a concurrent, therapeutic, anti-inflammatory mechanism could not be discounted. The mechanism of improved GI recovery conferred by NSAIDs therefore remains unclear. Interestingly, all of the included studies were published between 2005 and 2009, and only a handful of future trials are planned. The pathophysiology of ileus is uncertain. Previous evidence describes 2 distinct phases in its development, including a short-acting neurogenic phase and a longeracting inflammatory phase. 5 The use of opioid analgesia augments these mechanisms by activating peripheral µ-opioid receptors. The current review demonstrated convincing evidence that NSAIDs enhance GI recovery by reducing opioid requirements in the postoperative setting. Evidence of an anti-inflammatory effect was also demonstrated, but the relative contribution of this to GI recovery was unclear. NSAIDs exert their anti-inflammatory effects through inhibition of COX-1 and COX-2, subsequently leading to inhibition of prostaglandins. This is relevant in the days after surgery, where the effects of ileus are prob- ably mediated by a cascade of mast cells, macrophages, and inflammatory cytokines involving the bowel muscularis. 5 Previous research has shown that this inflammatory response is safely mitigated using pharmacological and nonpharmacological interventions, and, in doing so, the return of GI function can be accelerated. 4 On this notion, NSAIDs may represent a cost-effective and accessible intervention to improve GI recovery while also providing effective postoperative analgesia.
Although these properties are attractive, there is reluctance in prescribing NSAIDs after colorectal surgery. 2 Some have called for NSAIDs to be avoided until further research can better characterize their risk profile. 22 These concerns are likely influenced by 2 factors. The first is the risk of acute kidney injury, especially in highrisk patients undergoing invasive resectional surgery. Although the majority of acute kidney injury in this setting is mild, recent evidence has identified an increased risk of mortality 1 year after surgery. 8 The second is an apparent link between NSAIDs and anastomotic leak, demonstrated by several interventional and observational studies and quantified recently in a pooled metaanalysis. 23 In 1 prospective cohort of elective colorectal surgery, diclofenac was associated with increased risk of leak on multivariate analysis (OR = 7.16 (95% CI, 3.82-13.4); p < 0.001) but not with ibuprofen (OR = 1.54 (95% CI, 0.82-2.86); p = 0.18). 9 In another retrospective cohort, NSAIDs were associated with increased risk of leak (OR = 1.24 (95% CI, 1.01-1.56); p = 0.04), but when subanalyzed, this was isolated to emergency surgery only (OR = 1.70 (95% CI, 1.11-2.68); p = 0.01). 10 With a high risk of bias expected in both studies and with uncertain pathophysiology, these findings remain contentious but noteworthy. The results identify a number of opportunities for additional research, including essential steps to justify a definitive, phase 3 RCT of NSAIDs to reduce ileus. First, although NSAIDs accelerate GI recovery when measured using conventional outcomes of bowel function, the relevance of these to patients and their expectations is unclear. Contrasting results for commonly reported outcome measures (eg, time to first flatus and oral tolerance) make for difficult interpretation, and other complementary measures (eg, length of hospital stay) are flawed by organizational confounders. 24 The absence of meaningful, standardized, patient-focused outcomes is an ongoing challenge but is being addressed elsewhere.
14 Second, the interpretation of safety in this review is limited by small study populations and low event rates. Future RCTs will offer high-quality evidence for efficacy and effectiveness, but the feasibility of capturing sufficient events (eg, acute kidney injury and anastomotic leak) to determine safety is limited. Instead, large, well-conducted, observational studies will provide valuable information and are currently ongoing. 25 As long as NSAIDs remain recommended by enhanced recovery guidelines, their use as postoperative analgesia after colorectal surgery in low-risk patients is justified. However, additional investigation into their effects on GI recovery, including preclinical work, to elucidate the therapeutic mechanisms is warranted. 7 Third, the state of clinician and patient equipoise must be explored before considering an RCT with the expectation of definitive and generalizable results. Although it is arguable that patients remain in satisfactory equipoise, pre-existing biases held by the colorectal and perioperative community around complications (anastomotic leak and acute kidney injury) are an important barrier to recruitment. This should be addressed via a scoping exercise to determine how split equipoise can be addressed within the design of a phase 3 RCT. Finally, in considering future RCTs, the financial impact of delayed GI recovery on health services should be explored. If shown to be effective and safe, NSAIDs may represent a cost-effective and clinically accessible intervention in most healthcare systems. This is in contrast to other interventions, such as µ-receptor antagonists, which appear effective in clinical studies but have not entered clinical practice outside of the United States because of issues of licensing and cost. 4 Strengths and limitations of this review are recognized. The main strength is the inclusion of RCTs with low risk of bias, which permitted a meaningful synthesis of data. Consideration to the following limitations must also be balanced. First, all of the included RCTs were published between 2005 and 2009 and have not yet been replicated, possibly because of hesitancy over the perceived risks of NSAIDs. In the meantime, an NSAID tested in 1 of the included studies (valdecoxib) has since been removed from international markets because of safety concerns relating to cardiovascular adverse events. 19 Also, most of the included RCTs included open surgical technique, but minimally invasive techniques are increasingly favored. The data are therefore relatively outdated but represent the best available evidence with important implications for current practice. Second, meta-analysis of pooled data was not prospectively planned because of wide variation expected in outcome reporting; however, on inspection, a quantitative synthesis was determined to be feasible and informative. 12, 14 Although the methods used are justified, this should be interpreted with an element of caution as a deviation from protocol. Finally, the review is unable to offer a definitive answer on the role of NSAIDs in GI recovery, but this was not its aim. Endorsement by enhanced recovery guidelines, at the same time as safety concerns expressed by observational studies, has produced considerable uncertainty on the use of NSAIDs after colorectal surgery. This review sets out a proposed direction based on a balanced assessment of the literature to explore this further.
